ID   WM983B
AC   CVCL_6809
SY   WM-983B; WM 983B; WM983-B; WM-983/B; WC00066
DR   BTO; BTO:0005042
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 441
DR   BioSample; SAMN10987974
DR   cancercelllines; CVCL_6809
DR   Cell_Model_Passport; SIDM01397
DR   Coriell; WC00066
DR   Cosmic; 686406
DR   Cosmic; 1155557
DR   Cosmic; 1303082
DR   DepMap; ACH-000765
DR   GEO; GSM109048
DR   GEO; GSM887740
DR   GEO; GSM888835
DR   GEO; GSM952592
DR   IARC_TP53; 30190
DR   LiGeA; CCLE_332
DR   PharmacoDB; WM983B_1666_2019
DR   Progenetix; CVCL_6809
DR   Rockland; WM983B-01-0001
DR   Wikidata; Q54994346
RX   PubMed=2068080;
RX   PubMed=2253310;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=21156289;
RX   PubMed=22460905;
RX   PubMed=23285177;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   HLA typing: A*01:01,29:02; B*14:02,37:01; C*06:02,08:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; PubMed=21156289; DepMap; Wistar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Phe (c.832_833CC>TT); Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.75%; Native American=0%; East Asian, North=5.11%; East Asian, South=0%; South Asian=5.18%; European, North=22.68%; European, South=64.28% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: deletion of D18S51: 14.
CC   Discontinued: Coriell; WC00066; probable.
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
ST   Source(s): Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 11,12
ST   D19S433: 10,14
ST   D21S11: 29,31.2
ST   D2S1338: 25,27
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 11
ST   D8S1179: 8,13
ST   FGA: 20,23
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6808 ! WM983A
OI   CVCL_A338 ! WM983C
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 29
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023;
RA   Villanueva J., Vultur A., Lee J.T., Somasundaram R.,
RA   Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W.,
RA   Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K.,
RA   Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A.,
RA   Sosman J.A., Nathanson K.L., Herlyn M.;
RT   "Acquired resistance to BRAF inhibitors mediated by a RAF kinase
RT   switch in melanoma can be overcome by cotargeting MEK and
RT   IGF-1R/PI3K.";
RL   Cancer Cell 18:683-695(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23285177; DOI=10.1371/journal.pone.0052760;
RA   Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J.,
RA   Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H.,
RA   Schuchter L.M., Clark D.P.;
RT   "Functional profiling of live melanoma samples using a novel automated
RT   platform.";
RL   PLoS ONE 7:E52760-E52760(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//